Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
Competitively inhibits 3- hydroxy-3 methylglutaryl co-enzyme A [HMG- COA] reductase, the enzyme that catalyses the early rate-limiting step in cholesterol biosynthesis conversion of HMG-Co A to mevalonate.
Monitor liver functions; not of great benefit in homozygous familial hypercholester- oleamia; heavy alcoholics; if myopathy is diag- nosed or suspected discontinue.
Pregnancy and lactation; hypersensitivity reaction to the drug; active liver disease or unexplained persistent defects in liver function tests; children under 18 years; impaired renal functions.
GI disturbances; myopathy; insomnia; UTI; tooth disorders; sinusitis.